Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Study of Neoadjuvant Therapy for Resectable Locally Advanced Gastric Cancer with PD-1 Antibody or in Combination with Apatinib ± S1±Oxaliplatin

NCT03878472 is registered in ClinicalTrials.gov with Qilu Hospital of Shandong University as lead sponsor.

NCT NCT03878472
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03878472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Study of Neoadjuvant Therapy for Resectable Locally Advanced Gastric Cancer with PD-1 Antibody or in Combination with Apatinib ± S1±Oxaliplatin
Lead sponsor
Qilu Hospital of Shandong University
Phase
Phase 2
Overall status
Completed
Start date
April 1, 2019
Completion date
May 31, 2024
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer